“Global Neurostimulation Devices market set to grow to $13bn by 2024” says new Visiongain report

28 November 2018
Pharma

Visiongain has launched a new pharma report Global Neurostimulation Devices Market 2019-2029: Spinal Cord Stimulators, Deep Brain Stimulators, Vagus Nerve Stimulators, Sacral Nerve Stimulators, Cortical Stimulators, Epilepsy, Pain Management, Hearing Loss, Incontinence, Gastroparesis, Parkinson’s Disease

Neurostimulation is an advanced treatment which helps to reduce certain types of chronic pain. Neurostimulation works by intercepting pain signals before they reach the brain. are different types of neurostimulation devices available in the market, namely spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, sacral nerve stimulators, and cortical stimulators among others.

The lead analyst of the report commented "The leading medical device manufacturers are focusing on entering the emerging Asia-Pacific & Latin American countries to open manufacturing facility to capture the low-cost manufacturing advantage and to cater the significantly rising demand for medical devices from these regions. Thus, rising demand for medical devices from emerging markets is expected to create significant opportunities for global neurostimulation devices market vendors and the overall market."

Leading companies featured in the report include Advanced Bionics, Boston Scientific Corporation, Cochlear ltd, Cyberonics, Medtronic, Neuronetics Inc, Nervo Corp., Cogentic Medical Inc, St Jude Medicall, NDI Medical

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever